US equity markets recorded a slight increase in volatile trade, fall in biotechnology shares was offset by gains in energy shares.
Six of the 10 major S & P sectors were lower, led by a decline in health shares of 2.15%.
Abbott Labs was down 8.8% after reporting a drop in revenue.
Facebook grew by 12.2 percent after the largest social network in the world reported a 52 percent jump in revenue.
Biotech industry Nasdaq is down 3.5 percent, the decline of Celgene is the largest 4.8%
11% reduction for Incyte also pulled the index lower after the company announced it would stop research for the treatment of cancer.
S & P 500 is up 0.4 percent 1,890.42, and the Nasdaq Composite index is 0.76 percent, at 4,502.17.
Bond markets, yields on government securities with a growth on Thursday as oil prices rebounded, raising expectations that inflation may rise, which is negative for bonds.
The benchmark 10 year Treasury down 5/32 in price to -2.02%.
Thirty-year bonds went down to 7/32 in price to -2.82%.
25 Canada Square, Level 33, office 50, Canary Wharf London, E14 5LQ +44 20 3608 6256
World Financial Markets - 0700 17 600 Varchev Exchange - 0700 115 44
Varchev Finance Ltd is registered in the FCA (FINANCIAL CONDUCT AUTHORITY) with a passport in the United Kingdom: FCA, United Kingdom - registration number: 494 045, which allows provision of financial services in the United Kingdom.
Varchev Finance Ltd strictly comply with the statutes of the European directive MiFID (Markets in Financial Instruments). targeting increased efficiency, transparency and uniformity of financial instruments.
Varchev Finance Ltd is authorized and regulated by the Financial Supervision Commission - Sofia, Bulgaria: License number RG-03-02-05 / 15.03.2006
The information on this site is not intended for distribution or use by any person in any country or jurisdiction where such distribution or use would be contrary to local law or regulation.
Disclaimer:
CFDs are complex instruments and come with a high risk of losing money rapidly due to leverage. 63,41% of retail investor accounts lose money when trading CFDs with this provider. You should consider whether you understand how CFDs work, and whether you can afford to take the high risk of losing your money.